Cardiac hypertrophy is not a required compensatory response to short- term pressure overload

Circulation

Volumn 101, Issue 24, 2000, Pages 2863-2869

  Hill, Joseph A ^a   Karimi, Mohsen ^a   Kutschke, William ^a   Davisson, Robin L ^a   Zimmerman, Kathy ^a   Wang, Zhengyi ^a   Kerber, Richard E ^a   Weiss, Robert M ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Calcineurin; Cyclosporine; Hypertrophy

Indexed keywords

CALCINEURIN; CYCLOSPORIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE WALL; HEART STRESS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; HEART VENTRICLE VOLUME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034691296     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.24.2863     Document Type: Article

References (37)

1. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-64.
2. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
3. McKinsey TA, Olson EN. Cardiac hypertrophy: sorting out the circuitry. Curr Opin Genet Develop. 1999;9:267-274.
4. Chien KR, Grace A, Hunter JJ. Molecular and cellular biology of cardiac hypertrophy and failure. In: Chien KR, Breslow JL, Leiden JM, et al, eds. Molecular Basis of Cardiovascular Disease: A Companion to Braunwald's Heart Disease. Philadelphia, Pa: WB Saunders Co; 1999:211-250.
5. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens. 1989;11:1325-1350.
6. q interface to inhibit in vivo pressure overload myocardial hypertrophy. Science. 1998;280:574-577.
7. Sussman MA, Lim HW, Gude N, et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998;281:1690-1693.
8. Meguro T, Hong C, Asai K, et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. 1999;84:735-740.
9. Shimoyama M, Hayashi D, Takimoto E, et al. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation. 1999; 100:2449-2454.
10. 2-terminal kinases. J Clin Invest. 1999;104:391-398.
11. Molkentin JD, Lu J-R, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
12. Dunn SE, Burns JL, Michel RN. Calcineurin is required for skeletal muscle hypertrophy. J Biol Chem. 1999;274:21908-21912.
13. 2+-dependent calcineurin signalling pathway. Nature. 1999;400:576-581.
14. Musarò A, McCullagh KJA, Naya FJ, et al. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature. 1999;400:581-585.
15. Clipstone NA, Fiorentino DF, Crabtree GR. Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes. J Biol Chem. 1994;269:26431-26437.
16. Husi H, Luyten MA, Zurini MG. Mapping of the immunophilin-immunosuppressant site of interaction on calcineurin. J Biol Chem. 1994; 269:14199-14204.
17. Rockman HA, Knowlton KU, Ross J Jr, et al. In vivo murine cardiac hypertrophy: a novel model to identify genetic signaling mechanisms that activate an adaptive physiological response. Circulation. 1993;87(suppl VII):VII-14-VII-21.
18. Batiuk TD, Urmson J, Vincent D, et al. Quantitating immunosuppression: estimating the 50% inhibitory concentration for in vivo cyclosporine in mice. Transplantation. 1996;61:1618-1624.
19. Zhang W, Kowal RC, Rusnak F, et al. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res. 1999;84:722-728.
20. Ding B, Price RL, Borg TK, et al. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res. 1999;84:729-734.
21. + current modulates repolarization and excitation-contraction coupling in adult mouse ventricle. J Physiol. 1997;504:557-563.
22. Schiller NB, Acquatella H, Ports TA, et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation. 1979;60: 547-555.
23. Luo Z, Shyu K-G, Gualberto A, et al. Calcineurin inhibitors and cardiac hypertrophy. Nat Med. 1998;4:1092-1093.
24. Müller JG, Nemoto S, Laser M, et al. Calcineurin inhibition and cardiac hypertrophy. Science. 1998;282:1007a.
25. Oikawa Y, Shirato K, Sakuma M, et al. The responses of left ventricular end-systolic pressure-diameter relationship to acute pressure overload induced by aortic constriction. Acta Physiol Scand. 1993;149:273-281.
26. Wiesner RJ, Ehmke H, Faulhaber J, et al. Dissociation of left ventricular hypertrophy, β-myosin heavy chain gene expression, and myosin isoform switch in rats after ascending aortic stenosis. Circulation. 1997;95: 1253-1259.
27. Von Anrep G. On the part played by the suprarenals in the normal vascular reactions of the body. J Physiol. 1912;45:307-317.
28. Knowlton FP, Starling EH. The influence of variations in temperature and blood pressure on the performance of the isolated mammalian heart. J Physiol Lond. 1912;44:206-219.
29. Sarnoff SJ, Mitchell JH, Gilmore JP, et al. Homeometric autoregulation in the heart. Circ Res. 1960;8:1077-1091.
30. Walston A, Rembert JC, Fedor JM, et al. Regional myocardial blood flow after sudden aortic constriction in awake dogs. Circ Res. 1978;42:419-425.
31. Nichols CG, Hanck DA, Jewell BR. The Anrep effect: an intrinsic myocardial mechanism. Can J Physiol Pharmacol. 1988;66:924-929.
32. 2+-dependent heterometric and homeometric autoregulation in hypertrophied rat heart. Am J Physiol. 1989;256:H1139-H1147.
33. Yang X-P, Liu Y-H, Shesely EG, et al. Endothelial nitric oxide gene knockout mice: cardiac phenotypes and the effects of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension. 1999;34:24-30.
34. Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med. 1999;5:246-247.
35. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397: 530-534.
36. Walsh RA. Calcineurin inhibition as therapy for cardiac hypertrophy and heart failure: requiescat in pace? Circ Res. 1999;84:741-743.
37. G-nitro-L-arginine methyl ester-induced hypertension: novel molecular adaptation to systolic load in absence of hypertrophy. Circulation. 2000;101:423-429.